Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
Novo Nordisk has implemented a price reduction for Wegovy in India, with the highest dose (2.4 mg) now priced at ₹16,400 monthly, a decrease from the previous ₹24,389.06. A document sent to distributors by Novo Nordisk India confirms this change. The lowest dose (0.25 mg) will now be sold at ₹10,850 per month, down from ₹16,260.94.
The price cut factors in the impact of GST 2.0.
Vikrant Shrotriya, managing director at Novo Nordisk India, stated that the company listened to both patient and doctor communities and took proactive steps for the benefit of the public.
These weight-loss medications, including Wegovy and Mounjaro, belong to the class of GLP-1 receptor agonists. These treatments promote a prolonged feeling of fullness and are prescribed for both obesity and diabetes. The price reduction occurred shortly after Mounjaro became the top-selling weight-loss drug in India by value in October.
According to Vishal Manchanda, an analyst at Systematix Institutional Equities, this price adjustment could be a preemptive move as generics are anticipated to enter the market in 2026. A reduced price point could help Novo Nordisk maintain competitiveness, especially considering Mounjaro's current success in India. Health tracking apps like Shotlee can help monitor the effectiveness of these drugs.
The active pharmaceutical ingredient in Wegovy, semaglutide, will lose its patent protection in India in March 2026. This opens the door for generic drug manufacturers to enter the market.
Reflecting the market's significance, both Novo Nordisk and Eli Lilly have partnered with local pharmaceutical companies, Emcure Pharmaceuticals Ltd. and Cipla Ltd., respectively. This collaboration aims to market Wegovy and Mounjaro under local brand names while maintaining the same cost. Experts suggest that this strategy will broaden the distribution of these weight-loss drugs throughout India.
